Anatomical implant region - a critical determinant for the osteogenic potency of small extracellular vesicles and rhBMP-2
Deininger C., Wagner A., Wichlas F., Rohde E., Freude T., Deluca A.
Animal Study, published in Eur J Trauma Emerg Surg (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Eur J Trauma Emerg Surg (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41410757
- PMCID
- PMC12715041
- DOI
- 10.1007/s00068-025-03036-w
Abstract (original English)
Purpose Mechanical stabilization is crucial for bone healing, yet complex fractures, particularly osteoporotic or comminuted, remain challenging due to impaired implant osseointegration, resulting in implant loosening or non-unions. This study investigated whether co-application of small extracellular vesicles (sEVs) derived from human umbilical cord mesenchymal stromal cells (hUC-MSC-sEVs) with a low dose of recombinant human bone morphogenetic protein 2 (rhBMP-2) could enhance screw implant osseointegration. Methods A novel small animal model was established to evaluate the effect of anatomical femur regions on screw integration. Six weeks postoperatively, bone formation and bone-implant contact were assessed by micro-computed tomography and descriptive histology. Biomechanical stability was determined using pull-out tests. Results Outcomes differed significantly between the proximal and distal implant locations, with no improvements in osseointegration observed in the distal region. In the proximal region, application of hUC-MSC-sEVs alone did not significantly improve osseointegration, whereas local application of 1.5 µg rhBMP-2 resulted in measurable biomechanical improvements. No additive or synergistic effects were observed when sEVs were co-administered with rhBMP-2. Descriptive histology supported these findings, demonstrating the most pronounced bone formation at the
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.